Kymera Therapeutics (KYMR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.32
- Estimate
- -$1.27
- Surprise
- -4.3%
- Score today
- 4.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Kymera Therapeutics (KYMR) reported a wider loss than forecast — adjusted EPS of -$1.32 against the -$1.27 estimate (a 4.3% shortfall).
Coverage in the report window
- Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150 — benzinga, 2026-10-30
- RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116 — benzinga, 2026-10-30
- Analysts Adjust Price Targets for Kymera Therapeutics — fiscal.ai, 2026-10-30
Where TrendMatrix's rating stands now
TrendMatrix currently rates KYMR Sell at 4.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -4.3% surprise compares with a +0.4% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Quality below floor (1.8 < 4.0)
- Momentum score 2.8/10 — below 4.5 minimum
- Reward/Risk 0.8:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $119.39
- Price target
- $130.70
- Stop
- $111.03
- Upside to target
- +9.5%
- Reward-to-risk
- 0.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
KYMR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $10.34B
- P/E (fwd)
- -23.7
- 52-week range
- $63.69–$142.92
- Off 52-week high
- 16.5%
- RSI (14)
- 43
- Volume vs avg
- 0.73×
- Score today
- 4.7/10